ATRT-02. THE DUAL MTORC1/2 INHIBITOR, TAK-228 COMBINES SYNERGISTICALLY WITH THE BH3 MIMETIC, OBATOCLAX TO IMPROVE SURVIVAL IN MICE BEARING ORTHOTOPIC XENOGRAFTS OF AT/RT

mTOR activation drives tumorigenicity by regulating transcription factor expression and downstream growth and survival pathways. We have previously shown that mTORC1 and mTORC2 are highly activated in AT/RT and the dual mTORC1/2 inhibitor, TAK-228 (Sapanisertib) improves survival in mice bearing ort...

Descripción completa

Detalles Bibliográficos
Autores principales: Findlay, Tyler, Parkhurst, Ashlyn, Wang, Sabrina, Eberhart, Charles, Raabe, Eric, Rubens, Jeffrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Atypical Teratoid Rhabdoid Tumors
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168110/
http://dx.doi.org/10.1093/neuonc/noab090.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168110/
http://dx.doi.org/10.1093/neuonc/noab090.002

Ejemplares similares